MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.05 USD
-0.05 (-1.61%)
Updated Apr 26, 2024 03:44 PM ET
After-Market: $3.08 +0.03 (0.98%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Brokerage Reports
0 items in cart
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 121 - 140 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Analyst Day Summary; Busy 2014; Big Catalysts In Sight
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Positive AGM Update; Analyst Day Next Week; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Initiating Coverage with an OUTPERFORM Rating and $12 Price Target: Best in Class Pracinostat Should Shine
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Intriguing ME-344 Data; Target Upped to $20 on Pipeline Entirety
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
PI3K Inhibitor Acquired; Pracinostat Chugging Along; Nice Positioning
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Takeaways From the 25th ROTH Conference; Reiterate Buy and $16 PT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Management Update; Fine Tuning Pracinostat''s Path; Target Upped to $16
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Promising Pracinostat Data at ASH Setting Pivotal Stage; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Healthcare -ASH 2012 Preview: Expecting Exciting Data in Atlanta
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Financing Risk Removed and Looking Toward ASH; Target to $2.50
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
European Patent Issued for ME-344; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
F2012 Results; Ramping Up Clinical Programs Nicely
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.